[PDF] [PDF] Complete thesis - Rijksuniversiteit Groningen

[PDF] CD033418 cddw2018_exhibitabstractguideindd - Canadian

FLOOR PLAN: MAIN MEZZANINE and CONVENTION FLOOR Main Mezzanine diagnosis between Irritable Bowel Syndrome (IBS) and Inflammatory Bowel areas, procedure documentation, image management, infection daily and almost all hospitals, with a National Network U1043, INSERM, Toulouse, France; 2

[PDF] Complete thesis - Rijksuniversiteit Groningen

Both national and international treatment guidelines advise to use a step?up protocol of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel daily functioning of the child may additionally guide management Participants defecated onto a stool collection sheet (Alere Health BV, The Netherlands)

[PDF] fusion indd - www6inrafr

Daily growth, from clock gene expression to the phospho-proteome and biomass 12:05-12:20 Seed Longevity of Arabidopsis Natural Variations after Priming Treatments Masanori Kaji Light sheet microscopy: a versatile tool for single cell calcium analysis specific mutants, markers and protocols that now provide an

[PDF] APRES 29-3 for pdfindd

issue a limited supply (3–5 days) of medication, so the patient may need another Paris, France 1 - manufacturer guidelines define patients with mild asthma as those who experience contact with the study nurse, a detailed written action plan, and were sympathetic dystrophy), fibromyalgia, irritable bowel syndrome

[PDF] 30 de enero, Día Mundial de la PAZ - Anciens Et Réunions

[PDF] 30 décembre 2015 - Gestion De Projet

[PDF] 30 découverte des honneurs cachés - Anciens Et Réunions

[PDF] 30 dessins humoristiques sur la dette le chômage et la précarité 08 - Anciens Et Réunions

[PDF] 30 ème RALLYE NATIONAL TOUT TERRAIN DUNES ET MARAIS - Anciens Et Réunions

[PDF] 30 euros pour une aprem au TOP!!!

[PDF] 30 F 1 - Archives départementales de la Nièvre

[PDF] 30 Gratinierte King Prawns in Kurkuma

[PDF] 30 H Sœurs de la Croix de Magnac-Laval (1664) - France

[PDF] 30 INSTITUTIONS FAISANT APPEL A LA GÉNÉROSITÉ PUBLIQUE - France

[PDF] 30 Jahre - Friedrichstrasse.de

[PDF] 30 Jahre Casino Tanzclub "Rot

[PDF] 30 Jahre Erfolgsstory

[PDF] 30 Jahre ERP: Rück- und Ausblick

[PDF] 30 Jahre Hausnotruf-Dienst

8QLYHUVLW\RI*URQLQJHQ

+HLGD$QNH

VYHUVLRQSXEOLVKHU

V3')LI\RXZLVKWRFLWHIURP

3XEOLVKHU

&RS\ULJKW

DPHQGPHQW

7DNHGRZQSROLF\

'RZQORDGGDWH

PATIENT-RELEVANT OUTCOMES

OF STOOL TESTING IN PEDIATRIC

INFLAMMATORY BOWEL DISEASE

Anke Heida

The research described in this thesis was performed at the Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen,

The Netherlands.

Zorgverzekeraars, CisBio Bioassays, BÜHLMANN Laboratories AG.

University of Groningen

BÜHLMANN Laboratories AG

CisBio Bioassays

Dr. Falk Pharma Benelux BV

Ferring BV

Tramedico BV

© A. Heida, 2017

All rights served. No part of this thesis may be reproduced, distributed, stored in a retrieval

Patient-relevant outcomes of stool

bowel disease

Proefschrift

Anke Heida

Promotor

Copromotor

Beoordelingscommissie

Paranimfen

CONTENTS

Part I: Screening

Chapter 2

Chapter 5

Part II: Monitoring

Chapter 9

Chapter 10

1 |13 0

INFLAMMATORY BOWEL DISEASE

14|

Chapter 1

SELECTING CHILDREN SUSPECTED OF IBD FOR ENDOSCOPY

|15 1 0 Out

MANAGING CHILDREN AND TEENAGERS WITH IBD

16|

Chapter 1

mucosal healing |17 1 0 Figure 3: Targets for disease monitoring along the disease progression pathway of luminal

Symptom scores are subject

to bias if disorders. for teenagers. 60,61
63

12 months period.

66

In the second scenario, the level of a single

following 12 months. 67
In the second part of this thesis we aim to decrease the burden of IBD and to improve 18|

Chapter 1

OUTLINE OF THIS THESIS

Chapter 7

|19 1 0 8 chapter 11 20|

Chapter 1

REFERENCES

|21 1 0 22|

Chapter 1

2 28|

Chapter 2

ABSTRACT

|29 2 0

INTRODUCTION

METHODS

30|

Chapter 2

RESULTS

|31 2 0 IBD- diagnoses Non-

IBD diagnoses

32|

Chapter 2

normal

DISCUSSION

|33 2 0

CONCLUSIONS

34|

Chapter 2

REFERENCES

3 38|

Chapter 3

ABSTRACT

|39

Reference value calgranulin C

INTRODUCTION

40|

Chapter 3

MATERIALS AND METHODS

|41

Reference value calgranulin C

42|

Chapter 3

RESULTS

Healthy

|43

Reference value calgranulin C

44|

Chapter 3

DISCUSSION

|45

Reference value calgranulin C

Phase I: proof of concept study

Phase I-II: explanatory study

Phase III: real world study

Fecal S100A12

Fecal S100A12

controls Assay

Age of

46|

Chapter 3

CONCLUSIONS

|47

Reference value calgranulin C

REFERENCES

48|

Chapter 3

SELECTING CHILDREN WITH SUSPECTED

INFLAMMATORY BOWEL DISEASE FOR

ENDOSCOPY WITH THE CALGRANULIN C OR

THE CACATU STUDY

A. Heida, E. van de Vijver, A.C. Muller Kobold, P.F. van Rheenen 52|

Chapter 4

ABSTRACT

ETHICS AND DISSEMINATION

STRENGTHS AND LIMITATIONS OF THIS STUDY

|53

Protocol of CACATU study

INTRODUCTION

METHODS

54|

Chapter 4

Major criteria

Minor criteria

|55

Protocol of CACATU study

56|

Chapter 4

Timeline

|57 0 58|

Chapter 4

Diagnosis: No IBD

Fecal Calgranulin C

Fecal

TotalǀнdžǁнLJͲ

Diagnosis: IBD

Fecal Calgranulin C

Fecal w x w x s t s t

Recruitment

|59

Protocol of CACATU study

60|

Chapter 4

|61

Protocol of CACATU study

62|

Chapter 4

DISCUSSION

et al |63

Protocol of CACATU study

64|

Chapter 4

REFERENCES

5 68|

Chapter 5

ABSTRACT

|69 5 0

INTRODUCTION

70|

Chapter 5

METHODS

|71 5 0 72|

Chapter 5

High risk of IBDLow risk of IBD

354
17 337
142
90
52195
19 176
316
|73 5 0

RESULTS

A B )"$. 0(2$",)(0(/ ..(0 !)$!,3$)/5 (+%$"0(,+

12$+()$-,)5-/

,)(0 .5.$"0 )1)"$.

1+.$) 0$#.$"0 )#(/$ /$

"0,/$(+0,)$. +"$ -5),.(& /0.(0(/ $%)14$/,-' &(0(/ (/"$)) +$,1/ *#%/!1)3%#-*)1)0 /-(,0$)0%!0% ,#*!00)&)%$ //)1!"*%"-4%*06 ),&%#1)-,

23%,)*%.-*6.0

-*)1!/6/%#1!*2*#%/

2,/%*!1%$/%#1!*$)0%!0%

!#1-0%),1-*%/!,#% %*)!#$)0%!0% .6*-/)'!01/)1)0 %&*25%0-.(!')1)0 )0#%**!,%-20 74|

Chapter 5

Alarm symptoms

Blood tests

Stool tests

|75 5 0

High risk

1

NPV ϭϬϬ;ϭϬϬͲϭϬϬͿϵϳ͘Ϯ;ϵϯ͘ϳͲϵϵ͘ϬͿϳϵ͘Ϭ;ϲϴ͘ϳͲϴϲ͘ϱͿϵϮ͘Ϯ;ϴϴ͘ϭͲϵϱ͘ϯͿϵϯ͘ϵ;ϴϯ͘ϰͲϵϳ͘ϵͿϵϲ͘ϯ;ϵϯ͘ϭͲϵϴ͘ϯͿ

Low risk

2

PPV ϰ͘Ϭ;ϯ͘ϯͲϰ͘ϳͿϲϴ͘ϱ;ϱϳ͘ϱͲϳϳ͘ϴͿϮϱ;ϵ͘ϴͲϱϬ͘ϲͿϴϯ͘ϯ;ϲϵ͘ϱͲϵϮ͘ϳͿϭϱ͘ϰ;ϲ͘ϰͲϯϮ͘ϳͿϴϱ͘ϱ;ϳϮ͘ϰͲϵϰ͘ϭͿ

Complete

cohort 3

PPV ϳϮ͘ϳ;ϲϯ͘ϴͲϴϭ͘ϬͿϵϮ͘ϳ;ϴϰ͘ϲͲϵϴ͘ϰͿϵϰ͘ϴ;ϴϳ͘ϴͲϵϵ͘ϯͿ

2 76|

Chapter 5

|77 5 0

IBD Non-IBD

lin C

;ђŐͬŐͿCalgranu

lin C

DISCUSSION

78|

Chapter 5

|79 5 0 80|

Chapter 5

CONCLUSIONS

|81 5 0

REFERENCES

82|

Chapter 5

|83 84|

Chapter 5

;ђŐͬŐͿCalgranulin C ;ђŐͬŐͿBacterial and parasite PCRRisk- |85 5 0 ;ђŐͬŐͿCalgranulin C ;ђŐͬŐͿBacterial and parasite PCRRisk-

CLINICAL UTILITY OF FECAL CALPROTECTIN

MONITORING IN ASYMPTOMATIC PATIENTS

A

SYSTEMATIC REVIEW AND PRACTICAL

GUIDE

A. Heida, K.T. Park, P.F. van Rheenen

90|

Chapter 6

ABSTRACT

BACKGROUND

METHODS

RESULTS

|91 6 0

INTRODUCTION

92|

Chapter 6

Validity

clinical indices protein progression treatment |93 0

METHODS

94|

Chapter 6

RESULTS

|95 6 0 mn52CAAL 96|

Chapter 6

StudyN of

in follow upAge group

Study aim

with Fecal

De Vos

Jauregui-

|97 6 0

Lasson

Molander

Yamamoto

Total552ϯϯ͘ϯй

98|

Chapter 6

standardFlow and standard

De Vos

Jauregui-

Lasson

Molander

Yama- moto |99 6quotesdbs_dbs19.pdfusesText_25